Michele Quaia

Michele Quaia

Auto-generated profile, based on publicly available information

Michele Quaia

Centro di Riferimento Oncologico, Aviano, Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in EBioMedicine
Verified
Journal Article
Open access
AVAlessandra Viel
Alessandra Viel
ABAlessandro Bruselles
Alessandro Bruselles
EMEttore Meccia
Ettore Meccia
MFMara Fornasarig
Mara Fornasarig
MQMichele Quaia
Michele Quaia
MBMargherita Bignami
Margherita Bignami
8-Oxoguanine, a common mutagenic DNA lesion, generates G:C>T:A transversions via mispairing with adenine during DNA replication. When operating normally, the MUTYH DNA glycosylase prevents 8-oxoguanine-related mutagenesis by excising the incorporated adenine. Biallelic MUTYH mutations impair this enzymatic function and are associated with colorectal cancer (CRC) in MUTYH-Associated Polyposis (MAP) syndrome. Here, we perform whole-exome sequencing that reveals a modest mutator phenotype in MAP CRCs compared to sporadic CRC stem cell lines or bulk tumours. The excess G:C>T:A transversion mutations in MAP CRCs exhibits a novel mutational signature, termed Signature 36, with a strong sequence dependence. The MUTYH mutational signature reflecting persistent 8-oxoG:A mismatches occurs frequently in the APC, KRAS, PIK3CA, FAT4, TP53, FAT1, AMER1, KDM6A, SMAD4 and SMAD2 genes that are associated with CRC. The occurrence of Signature 36 in other types of human cancer indicates that DNA 8-oxoguanine-related mutations might contribute to the development of cancer in other organs.

15 June 1996 in Cancer
Verified
Journal Article
Closed access
PDF file
EGEnzo Galligioni
Enzo Galligioni
MQMichele Quaia
Michele Quaia
AMAlberto Merlo
Alberto Merlo
Antonino CarboneAntonino Carbone
Antonino Carbone
ASAntonella Spada
Antonella Spada
TCThe Gruppo Oncologico Clinico Coope
The Gruppo Oncologico Clinico Coope

1 January 2008 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
GIGaetano Iaquinto
Gaetano Iaquinto
MFMara Fornasarig
Mara Fornasarig
MQMichele Quaia
Michele Quaia
NGNicola Giardullo
Nicola Giardullo
VDVittorio D'ONofrio
Vittorio D'ONofrio
RCRenato Cannizzaro
Renato Cannizzaro

1 May 1997 in European Journal of Cancer
Verified
Journal Article
Closed access
MSManuela Santarosa
Manuela Santarosa
DFD. Favaro
D. Favaro
MQM. Quaia
M. Quaia
EGE. Galligioni
E. Galligioni

5 March 2015 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
GCGiulia Cini
Giulia Cini
ICIleana Carnevali
Ileana Carnevali
MQMichele Quaia
Michele Quaia
ACAnna Maria Chiaravalli
Anna Maria Chiaravalli
PSPaola Sala
Paola Sala
AVAlessandra Viel
Alessandra Viel
Lynch syndrome (LS) is an inherited predisposition cancer syndrome, typically caused by germline mutations in the mismatch repair genes MLH1, MSH2, MSH6 and PMS2. In the last years, a role for epimutations of the same genes has also been reported. MLH1 promoter methylation is a well known mechanism of somatic inactivation in tumors, and more recently, several cases of constitutional methylation have been identified. In four subjects affected by multiple tumors and belonging to a suspected LS family, we detected a novel secondary MLH1 gene epimutation. The methylation of MLH1 promoter was always linked in cis with a 997 bp-deletion (c.-168_c.116+713del), that removed exon 1 and partially involved the promoter of the same gene. Differently from cases with constitutional primary MLH1 inactivation, this secondary methylation was allele-specific and CpGs of the residual promoter region were totally methylated, leading to complete allele silencing. In the colon tumor of the proband, MLH1 and PMS2 expression was completely lost as a consequence of a pathogenic somatic point mutation (MLH1 c.199G>A, p.Gly67Arg) that also abrogated local methylation by destroying a CpG site. The evidences obtained highlight how MLH1 mutations and epimutations can reciprocally influence each other and suggest that an altered structure of the MLH1 locus results in epigenetic alteration.

29 October 2012 in Oncogene
Verified
Journal Article
Open access
VRVitalba Ruggieri
Vitalba Ruggieri
EPElisa Pin
Elisa Pin
MRM T Russo
M T Russo
FBF Barone
F Barone
PDPaolo Degan
Paolo Degan
MBM Bignami
M Bignami
The DNA glycosylase MUTYH (mutY homolog (Escherichia coli)) counteracts the mutagenic effects of 8-oxo-7,8-dihydroguanine (8-oxodG) by removing adenine (A) misincorporated opposite the oxidized purine. Biallelic germline mutations in MUTYH cause the autosomal recessive MUTYH-associated adenomatous polyposis (MAP). Here we designed new tools to investigate the biochemical defects and biological consequences associated with different MUTYH mutations in human cells. To identify phenotype(s) associated with MUTYH mutations, lymphoblastoid cell lines (LCLs) were derived from seven MAP patients harboring missense as well as truncating mutations in MUTYH. These included homozygous p.Arg245His, p.Gly264TrpfsX7 or compound heterozygous variants (p.Gly396Asp/Arg245Cys, p.Gly396Asp/Tyr179Cys, p.Gly396Asp/Glu410GlyfsX43, p.Gly264TrpfsX7/Ala385ProfsX23 and p.Gly264TrpfsX7/Glu480del). DNA glycosylase assays of MAP LCL extracts confirmed that all these variants were defective in removing A from an 8-oxoG:A DNA substrate, but retained wild-type OGG1 activity. As a consequence of this defect, MAP LCLs accumulated DNA 8-oxodG in their genome and exhibited a fourfold increase in spontaneous mutagenesis at the PIG-A gene compared with LCLs from healthy donors. They were also hypermutable by KBrO3--a source of DNA 8-oxodG--indicating that the relatively modest spontaneous mutator phenotype associated with MUTYH loss can be significantly enhanced by conditions of oxidative stress. These observations identify accumulation of DNA 8-oxodG and a mutator phenotype as likely contributors to the pathogenesis of MUTYH variants.